CPC A61K 31/506 (2013.01) [A61P 35/00 (2018.01)] | 15 Claims |
1. A method of treating a tumor, which comprises administering to a subject in need thereof a therapeutically effective amount of IN10018 or a pharmaceutically acceptable salt thereof and an epidermal growth factor receptor tyrosine kinase inhibitor, wherein the IN10018 has a structure of:
![]() and
the epidermal growth factor receptor tyrosine kinase inhibitor is selected from the group consisting of Icotinib, Afatinib, Crizotinib, Osimertinib (AZD9291), Almonertinib, Alflutinib (also known as Furmonertinib), EAI045, JBJ-25-02, BLU945, BLU701, TOB3804, BBT-176, ES-072, BPI-361175, CH7233163, and a pharmaceutically acceptable salt thereof.
|